Skip to main content

Advertisement

Table 1 Effect of SG2000 on the growth of canine cancer cells and canine normal cells following a 1 h or continuous (96 h) exposure

From: Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours

Cell Line Cell Type GI50 (nM)a
1 h Continuous
C2 Mast cell 0.33 ± 0.84b <0.03b
ARCE Mast cell >100 4.10 ± 0.87
CMeC-1 Melanoma, cutaneous (primary) >100 17.33 ± 2.33
CMeC-2 Melanoma, cutaneous (derived from CMeC-1, metastatic in mouse model) >100 11.0 ± 3.78
12 Melanoma, oral 63.63 ± 45 7.83 ± 1.16
KMeC Melanoma, oral 4.73 ± 2.22 <0.03
LMeC Melanoma, oral (metastatic mandibular lymph node) 24.0 ± 3.21 1.60 ± 0.79
DH82 Monocyte/macrophage/histiocytic sarcoma >100 4.0 ± 2.0
A72 Connective tissue tumour 47.0 ± 3.51 0.83 ± 0.07
DEN Haemangiosarcoma 45.0 ± 2.5 0.75 ± 0.08
D17 Osteosarcoma 47.5 ± 2.5 0.92 ± 0.57
CF33MG Mammary gland carcinoma 9.0 ± 3.58 0.99 ± 0.01
CF35MG Mammary gland (normal) >100 6.0 ± 0.86
MDCK Kidney epithelial (normal) >100 28.33 ± 8.33
  1. aGI50 values are the dose of drug required to inhibit growth by 50 %. Data shown are the mean ± standard deviation from three independent experiments
  2. bData are from the SRB assay except for cell line C2 which grows partly in suspension and where the GI50 value was determined using the MTT assay